ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis

NASDAQ:ADMA • US0008991046

16.47 USD
-0.11 (-0.66%)
Last: Mar 3, 2026, 11:24 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to ADMA. ADMA was compared to 520 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making ADMA a very profitable company, without any liquidiy or solvency issues. ADMA may be a bit undervalued, certainly considering the very reasonable score on growth This makes ADMA very considerable for value and quality investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year ADMA was profitable.
  • ADMA had a positive operating cash flow in the past year.
  • In multiple years ADMA reported negative net income over the last 5 years.
  • In multiple years ADMA reported negative operating cash flow during the last 5 years.
ADMA Yearly Net Income VS EBIT VS OCF VS FCFADMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • With an excellent Return On Assets value of 23.54%, ADMA belongs to the best of the industry, outperforming 97.12% of the companies in the same industry.
  • ADMA has a Return On Equity of 30.78%. This is amongst the best in the industry. ADMA outperforms 96.92% of its industry peers.
  • ADMA's Return On Invested Capital of 27.76% is amongst the best of the industry. ADMA outperforms 98.65% of its industry peers.
  • ADMA had an Average Return On Invested Capital over the past 3 years of 20.20%. This is in line with the industry average of 18.99%.
  • The last Return On Invested Capital (27.76%) for ADMA is above the 3 year average (20.20%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 23.54%
ROE 30.78%
ROIC 27.76%
ROA(3y)18.47%
ROA(5y)2.12%
ROE(3y)22.18%
ROE(5y)-5.51%
ROIC(3y)20.2%
ROIC(5y)N/A
ADMA Yearly ROA, ROE, ROICADMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • The Profit Margin of ADMA (28.80%) is better than 95.00% of its industry peers.
  • ADMA has a Operating Margin of 37.52%. This is amongst the best in the industry. ADMA outperforms 97.12% of its industry peers.
  • Looking at the Gross Margin, with a value of 57.39%, ADMA is in the better half of the industry, outperforming 77.69% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ADMA has grown nicely.
Industry RankSector Rank
OM 37.52%
PM (TTM) 28.8%
GM 57.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y35.81%
GM growth 5YN/A
ADMA Yearly Profit, Operating, Gross MarginsADMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • ADMA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, ADMA has more shares outstanding
  • ADMA has more shares outstanding than it did 5 years ago.
  • ADMA has a better debt/assets ratio than last year.
ADMA Yearly Shares OutstandingADMA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ADMA Yearly Total Debt VS Total AssetsADMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 18.36 indicates that ADMA is not in any danger for bankruptcy at the moment.
  • ADMA's Altman-Z score of 18.36 is amongst the best of the industry. ADMA outperforms 88.65% of its industry peers.
  • The Debt to FCF ratio of ADMA is 2.62, which is a good value as it means it would take ADMA, 2.62 years of fcf income to pay off all of its debts.
  • ADMA's Debt to FCF ratio of 2.62 is amongst the best of the industry. ADMA outperforms 93.08% of its industry peers.
  • ADMA has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.15, ADMA is doing worse than 63.46% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.62
Altman-Z 18.36
ROIC/WACC3.21
WACC8.64%
ADMA Yearly LT Debt VS Equity VS FCFADMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • ADMA has a Current Ratio of 6.71. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ADMA (6.71) is better than 67.69% of its industry peers.
  • A Quick Ratio of 3.74 indicates that ADMA has no problem at all paying its short term obligations.
  • ADMA has a Quick ratio (3.74) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 6.71
Quick Ratio 3.74
ADMA Yearly Current Assets VS Current LiabilitesADMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.00%, which is quite good.
  • ADMA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.63%.
  • The Revenue has been growing by 64.62% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)19.63%
Revenue growth 3Y49.04%
Revenue growth 5Y64.62%
Sales Q2Q%18.39%

3.2 Future

  • The Earnings Per Share is expected to grow by 35.23% on average over the next years. This is a very strong growth
  • ADMA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.85% yearly.
EPS Next Y53.85%
EPS Next 2Y41.43%
EPS Next 3Y38.57%
EPS Next 5Y35.23%
Revenue Next Year24.85%
Revenue Next 2Y22.97%
Revenue Next 3Y22.47%
Revenue Next 5Y19.85%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADMA Yearly Revenue VS EstimatesADMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
ADMA Yearly EPS VS EstimatesADMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 27.45 indicates a quite expensive valuation of ADMA.
  • Based on the Price/Earnings ratio, ADMA is valued cheaply inside the industry as 92.50% of the companies are valued more expensively.
  • ADMA is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.13, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 17.84, which indicates a rather expensive current valuation of ADMA.
  • 94.23% of the companies in the same industry are more expensive than ADMA, based on the Price/Forward Earnings ratio.
  • ADMA's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.11.
Industry RankSector Rank
PE 27.45
Fwd PE 17.84
ADMA Price Earnings VS Forward Price EarningsADMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.85% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, ADMA is valued cheaper than 91.15% of the companies in the same industry.
Industry RankSector Rank
P/FCF 142.61
EV/EBITDA 19.71
ADMA Per share dataADMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ADMA has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as ADMA's earnings are expected to grow with 38.57% in the coming years.
PEG (NY)0.51
PEG (5Y)N/A
EPS Next 2Y41.43%
EPS Next 3Y38.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ADMA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ADMA BIOLOGICS INC

NASDAQ:ADMA (3/3/2026, 11:24:02 AM)

16.47

-0.11 (-0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners93.5%
Inst Owner Change-2.89%
Ins Owners2.35%
Ins Owner Change3.92%
Market Cap3.92B
Revenue(TTM)510.17M
Net Income(TTM)146.93M
Analysts82.22
Price Target26.18 (58.96%)
Short Float %9.25%
Short Ratio8.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.01%
Min EPS beat(2)-1.96%
Max EPS beat(2)5.99%
EPS beat(4)1
Avg EPS beat(4)-7.27%
Min EPS beat(4)-31.17%
Max EPS beat(4)5.99%
EPS beat(8)4
Avg EPS beat(8)9.68%
EPS beat(12)6
Avg EPS beat(12)-7.7%
EPS beat(16)8
Avg EPS beat(16)-5.55%
Revenue beat(2)1
Avg Revenue beat(2)-0.66%
Min Revenue beat(2)-2.13%
Max Revenue beat(2)0.81%
Revenue beat(4)1
Avg Revenue beat(4)-1.78%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)0.81%
Revenue beat(8)5
Avg Revenue beat(8)3.94%
Revenue beat(12)9
Avg Revenue beat(12)4.07%
Revenue beat(16)13
Avg Revenue beat(16)4.88%
PT rev (1m)0%
PT rev (3m)-5.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.87%
Valuation
Industry RankSector Rank
PE 27.45
Fwd PE 17.84
P/S 7.69
P/FCF 142.61
P/OCF 77.83
P/B 8.22
P/tB 8.29
EV/EBITDA 19.71
EPS(TTM)0.6
EY3.64%
EPS(NY)0.92
Fwd EY5.6%
FCF(TTM)0.12
FCFY0.7%
OCF(TTM)0.21
OCFY1.28%
SpS2.14
BVpS2
TBVpS1.99
PEG (NY)0.51
PEG (5Y)N/A
Graham Number5.2
Profitability
Industry RankSector Rank
ROA 23.54%
ROE 30.78%
ROCE 34.51%
ROIC 27.76%
ROICexc 32.97%
ROICexgc 33.27%
OM 37.52%
PM (TTM) 28.8%
GM 57.39%
FCFM 5.39%
ROA(3y)18.47%
ROA(5y)2.12%
ROE(3y)22.18%
ROE(5y)-5.51%
ROIC(3y)20.2%
ROIC(5y)N/A
ROICexc(3y)25.15%
ROICexc(5y)N/A
ROICexgc(3y)25.44%
ROICexgc(5y)N/A
ROCE(3y)25.11%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y35.81%
GM growth 5YN/A
F-Score6
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.62
Debt/EBITDA 0.35
Cap/Depr 282.75%
Cap/Sales 4.49%
Interest Coverage 21.09
Cash Conversion 25.26%
Profit Quality 18.72%
Current Ratio 6.71
Quick Ratio 3.74
Altman-Z 18.36
F-Score6
WACC8.64%
ROIC/WACC3.21
Cap/Depr(3y)149.71%
Cap/Depr(5y)178.08%
Cap/Sales(3y)2.81%
Cap/Sales(5y)6.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y53.85%
EPS Next 2Y41.43%
EPS Next 3Y38.57%
EPS Next 5Y35.23%
Revenue 1Y (TTM)19.63%
Revenue growth 3Y49.04%
Revenue growth 5Y64.62%
Sales Q2Q%18.39%
Revenue Next Year24.85%
Revenue Next 2Y22.97%
Revenue Next 3Y22.47%
Revenue Next 5Y19.85%
EBIT growth 1Y37.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year88.74%
EBIT Next 3Y45.29%
EBIT Next 5Y35.13%
FCF growth 1Y-75.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.53%
OCF growth 3YN/A
OCF growth 5YN/A

ADMA BIOLOGICS INC / ADMA FAQ

What is the fundamental rating for ADMA stock?

ChartMill assigns a fundamental rating of 6 / 10 to ADMA.


What is the valuation status of ADMA BIOLOGICS INC (ADMA) stock?

ChartMill assigns a valuation rating of 7 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Undervalued.


How profitable is ADMA BIOLOGICS INC (ADMA) stock?

ADMA BIOLOGICS INC (ADMA) has a profitability rating of 7 / 10.


What is the financial health of ADMA BIOLOGICS INC (ADMA) stock?

The financial health rating of ADMA BIOLOGICS INC (ADMA) is 7 / 10.